Struggling to control your
Ulcerative Colitis?

See if the RHEA study is right for you.

If you’re living with ulcerative colitis (UC), you know the symptoms all too well – diarrhea, abdominal cramping, even unintended weight loss. And when your UC flares up, it can interfere with every aspect of daily life.

Although there are several medications for UC available, they don’t work for everyone, and sometimes cause unwanted side effects.

Right now, doctors at select centers in the US are accepting participants for a new clinical research study. The study is for an oral investigational medication that may help reduce UC signs and symptoms. The study medication is non-steroid and intended to work within the digestive system to reduce inflammation associated with ulcerative colitis.

If you’re 18 or older and either dependent on steroid medications to control your ulcerative colitis, or haven’t achieved lasting success with other UC treatments, you may qualify to participate. If you join, you will receive all study-related care at no cost from a local doctor, and will also be compensated for your time and travel.

Why Participate?

Many people with ulcerative colitis struggle to achieve lasting relief of their symptoms, or are dependent on steroid medications to deal with frequent flare-ups. The RHEA study is evaluating an investigational, non-steroid oral medication to see if it can reduce signs and symptoms associated with ulcerative colitis. By joining the RHEA Study, you will receive:

  • Evaluations of your ulcerative colitis from a local physician
  • Study medication and study-related medical care at no cost*
  • Compensation for your time and travel to attend study visits
  • The opportunity to help advance ulcerative colitis research to benefit others suffering from UC

* You do not need insurance to participate

 

Frequently Asked Questions
Clinical studies or trials are used to learn about the safety and effectiveness of new medications, medical devices, and medical procedures. Although there are many types of clinical trials, all must conform to strict rules set by local regulatory authorities. These rules help protect the rights and safety of those who volunteer to take part in clinical trials.
TD-1473 is the investigational medication being evaluated in the RHEA study. It is an oral, non-steroid mediation that is intended to act right within the digestive system to reduce inflammation associated with ulcerative colitis.
The RHEA study is intended for people who have been diagnosed with ulcerative colitis (UC), and are either dependent on steroid medications to control their symptoms, or have not achieved lasting symptom control with other UC medications.

No. If you qualify and choose to join the RHEA study, you will receive all study-related care at no cost. This includes the study medication, as well as any visits to your study doctor’s office. Health insurance is not required to participate.

The RHEA study is being conducted globally at approximately 230 study centers throughout North America, South America, Europe, Africa, and Asia.

If you join the study, your participation may last up to 16 months. During this time, you will be asked to meet with your local study doctor at regular intervals to provide feedback about your experiences and to evaluate your ulcerative colitis symptoms. You will be compensated for your time and travel to attend these visits.

As with all clinical studies, your participation is completely voluntary and you may choose to leave the study at any time without penalty or judgment.

To see if you might qualify for the study, and to get connected with your local study center, the next step is taking the pre-screening questionnaire. Please click here to get started.

See If You Qualify

To see if you might qualify for the RHEA study, and to get connected with your local study center to discuss the study further, please complete the questionnaire below.